Jump to main content
Jump to site search

Issue 60, 2018
Previous Article Next Article

Increased immune cell infiltration in patient-derived tumor explants treated with Traniplatin: an original Pt(IV) pro-drug based on Cisplatin and Tranilast

Author affiliations

Abstract

Elevated intra-tumoral immune infiltrate is associated with an improved prognosis in cancer of distinct origins. Traniplatin (TPT) is a novel platinum(IV) pro-drug based on Cisplatin (CDDP) and the marketed drug Tranilast. When compared in vitro to Cisplatin, TPT showed increased cytotoxic activity against colon and lung cancer cells but decreased activity against immune cells. In addition, TPT efficiency was evaluated in tumor explants derived from colorectal cancer samples from patients subjected to intended curative surgery. TPT induced strong intra-tumoral cytotoxic activity yet was associated with an elevated presence of immune cell infiltrate, suggesting a reduced cytotoxic activity against immune cells in colorectal cancer.

Graphical abstract: Increased immune cell infiltration in patient-derived tumor explants treated with Traniplatin: an original Pt(iv) pro-drug based on Cisplatin and Tranilast

Back to tab navigation

Supplementary files

Publication details

The article was received on 18 Mar 2018, accepted on 24 Apr 2018 and first published on 25 Apr 2018


Article type: Communication
DOI: 10.1039/C8CC02071J
Citation: Chem. Commun., 2018,54, 8324-8327

  •   Request permissions

    Increased immune cell infiltration in patient-derived tumor explants treated with Traniplatin: an original Pt(IV) pro-drug based on Cisplatin and Tranilast

    D. Lo Re, D. Montagner, D. Tolan, C. Di Sanza, M. Iglesias, A. Calon and E. Giralt, Chem. Commun., 2018, 54, 8324
    DOI: 10.1039/C8CC02071J

Search articles by author

Spotlight

Advertisements